Proposal to fund Erbitux for head and neck cancer in New Zealand

15 November 2017

New Zealand’s Pharmaceutical Management Agency PHARMAC said today that it proposes to fund cetuximab (Erbitux) from February 1, 2018 for the treatment of patients with locally advanced, non-metastatic, squamous cell cancer of the head and neck subject to certain clinical criteria being met.

Certain patients with locally advanced, non-metastatic, squamous cell cancer of the head and neck would be eligible for a funded course of treatment with cetuximab in combination with radiotherapy. The Agency estimates there would be around 40-50 patients per year who may be eligible for treatment with cetuximab under this proposal.

PHARMAC received an application from Merck Serono, the local unit of Germany’s Merck KGaA (MRK: DE), to fund cetuximab for the treatment of patients with locally advanced squamous cell carcinomas of the head and neck. The application has been reviewed by the Pharmacology and Therapeutics Advisory Committee (PTAC) as well as by PTAC’s Cancer Treatments Subcommittee, CaTSoP.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK